Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
about
The estrogen receptor joins other cancer biomarkers as a predictor of outcomeEndometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasVerteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cellsDual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsHER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Endometrial metastasis of lung adenocarcinoma: a report of two cases.Molecular staging of gynecological cancer: What is the future?The Therapeutic Challenge of Targeting HER2 in Endometrial CancerPhase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NA phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.Recent Advances in Endometrial Cancer.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.Oncolytic vaccinia virotherapy for endometrial cancerTargeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib.Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.Emerging drugs for endometrial cancer.Endometrial cancer: redefining the molecular-targeted approach.An update on the current pharmacotherapy for endometrial cancer.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsThe future role of molecular staging in gynecologic cancer.A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.Endometrial Carcinoma: Specific Targeted Pathways.Targeted endometrial cancer therapy as a future prospect.MUC1 stimulates EGFR expression and function in endometrial cancer.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.New therapies for advanced, recurrent, and metastatic endometrial cancers.HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.Clinical trials in gynecologic oncology: Past, present, and future.Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.Hierarchical closeness-based properties reveal cancer survivability and biomarker genes in molecular signaling networks.Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
P2860
Q26865554-BC12AFB6-4396-44E1-A050-088E61C0E959Q28074769-8084A490-F25E-48D4-A2E4-F8B931F1F65AQ33709820-CE002BF1-1451-4E65-BD8A-B9337836C196Q34714574-BB777A6D-759E-444A-8BFE-F0F6FA10C9AFQ35235832-E14FAC03-321F-4B68-81CB-18A53D9ECD52Q35647983-1A415CF4-B3FE-4005-947E-D7668CABAA92Q35940829-8BB90FA1-2C9E-4BD4-B0C6-FA32A9ED5F08Q36064912-D8467EB5-CB20-4F5A-9E45-3F4B9F0830FEQ36191443-CC80D1D2-FE02-465B-8DDC-367E554D26BDQ36274386-0B20951C-6C16-4035-85C4-2A7400F76069Q36407018-B8A9E736-9DF2-462D-A6FF-829753301513Q37620470-E5863F8A-12FA-465C-96F9-232CDA1A900DQ37625385-9C24C693-73A9-46AC-8FDC-38DB3267B686Q37671783-4D85B0A6-E191-44F4-A903-F04311EC87F2Q37688850-F556A881-CDD3-4F5A-B762-55B9C377CF44Q38194548-CDE5B564-51C9-43F5-8491-3806A537B250Q38203354-EE43B247-3746-450C-9CA8-377C16559D00Q38261469-293B2BC1-709B-46A2-8C20-40CF3DC8B7EDQ38454955-21A79559-DA2D-49DE-A251-06EF72B5186AQ38656675-8D29B35B-2CFB-422F-9A98-E8D546974DC5Q38753038-8AAE2270-EBA5-458B-B008-ABAD3CB00CD9Q38895754-B0863BFD-D0C5-40E4-9CE8-E38ACB4760F8Q38957038-E4D1D25D-E518-4B89-B3A9-17E40C7F2374Q38995713-4D5C65E0-DDD7-45FE-807C-944D7FFB3336Q39026766-2B66AF0A-7CE7-467A-A296-5AA25EF03BFDQ39454208-B3CF4C50-418A-41E8-9B19-CC9D42E5E0A3Q39840036-1864F438-9686-4885-BFDC-09267BFC1803Q45848384-D25A4FB0-51E9-4F0D-8677-2C8B0ED497C8Q47103210-CC1A9796-6004-482C-A8E2-7EBE3BF43CBFQ47370686-08E12C57-E78D-46DF-907D-B3B74B1C3C74Q47569610-F7089CBF-D32B-45A2-B473-0054D60EC0F9Q47796770-B77876C2-E8C6-44A1-B940-95F20D3DF3D6Q48212195-276A904B-6D5D-421D-AE2D-2685EB355592Q53178110-CB6AD838-9DD6-4EC9-BC74-C6821C332763Q55242072-13C17B57-F92C-4E04-9B99-268085FF5A07Q57169683-B0B0EC32-31E5-4C48-9655-1B293BEBA182
P2860
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Lapatinib and potential progno ...... r recurrent endometrial cancer
@ast
Lapatinib and potential progno ...... r recurrent endometrial cancer
@en
type
label
Lapatinib and potential progno ...... r recurrent endometrial cancer
@ast
Lapatinib and potential progno ...... r recurrent endometrial cancer
@en
prefLabel
Lapatinib and potential progno ...... r recurrent endometrial cancer
@ast
Lapatinib and potential progno ...... r recurrent endometrial cancer
@en
P2093
P2860
P1433
P1476
Lapatinib and potential progno ...... r recurrent endometrial cancer
@en
P2093
Andrew K Godwin
Edgar G Fischer
Heather A Lankes
Heidi Gray
Joan L Walker
Krishnansu Tewari
Michael W Sill
Ovadia Abulafia
Parviz Hanjani
Peter G Rose
P2860
P304
P356
10.1016/J.YGYNO.2012.07.127
P407
P577
2012-08-07T00:00:00Z